Research Letter

Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry

Data Availability Statement Aggregate data are available on the SECURE-IBD website (covidibd.org) and patient-level data are available through an application process noted on website.

Conflicts of interest These authors disclose the following: Ryan C. Ungaro: served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; received research support from AbbVie, Boehringer Ingelheim, Eli Lilly, and Pfizer. Richard B. Gearry: speaker fees and Scientific Advisory Boards for AbbVie and Janssen. Gilaad G. Kaplan: Honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer, and Takeda; received research support from Ferring, Janssen, Abbvie, GlaxoSmith Kline, Merck, and Shire; ownership of a patent (Treatment of Inflammatory Disorders, Autoimmune Disease, and PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. September 7. 2018). Michele Kissous-Hunt: speaker/consultant for AbbVie, Janssen, Takeda. James D. Lewis: personal fees from Johnson & Johnson Consumer Inc, grants, personal fees and other from Takeda Pharmaceuticals, personal fees and nonfinancial support from AbbVie, grants and personal fees from Janssen Pharmaceuticals, personal fees from Eli Lilly and Company, personal fees from Samsung Bioepis, personal fees from UCB, personal fees from Bristol-Myers Squibb, grants and personal fees from Nestle Health Science, personal fees from Bridge Biotherapeutics, personal fees from Celgene, personal fees from Merck, personal fees and other from Pfizer, personal fees from Gilead, personal fees from Arena Pharmaceuticals, personal fees from Protagonist Therapeutics. Siew C. Ng: honoraria for speaking or consultancy from Abbvie, Janssen, Ferring, Tillotts, and Takeda; research support from Ferring and AbbVie. Jean-Francois Rahier: lecture fees from AbbVie, MSD, Takeda, Pfizer, Ferring, and Falk, consulting fees from AbbVie, Takeda, Hospira, Mundipharma, MSD, Pfizer, GlaxoSK, and Amgen, and research support from Takeda and AbbVie. Walter Reinisch: speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult; consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC; advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC; received research funding from Abbott Laboratories, Abbvie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnsotik, and MSD. Jean-Francois Rahier: Consultation fee, research grant, or honorarium from Janssen, Pfizer, Abbvie, Takeda, Celgene, Nestlé Health Science, Nestlé Nutrition Institute. Flavio Steinwurz: Speaker and consultant for: AbbVie, Eurofarma, Ferring, Janssen, Pfizer, Sanofi, Takeda, and UCB. Michael D. Kappelman has consulted for AbbVie, Janssen, Pfizer, Eli Lilly, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from AbbVie and Janssen. Jean-Frederic Colombel: received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; received payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microba, Novartis, PBM Capital, Pfizer, Sanofi, Takeda, TiGenix, Vifor; and holds stock options in Intestinal Biotech Development. The remaining authors disclose no conflicts.

Funding This work was funded by the Helmsley Charitable Trust (2003-04445), Clinical and Translational Science Awards grant number UL1TR002489, T32DK007634 (Erica J. Brenner), K23KD111995-01A1 (Ryan C. Ungaro), and K23DK129762-01 (Manasi Agrawal). Additional funding provided by Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm.

Authors share co-first authorship.

Authors share co-senior authorship.